177 related articles for article (PubMed ID: 38178183)
1. ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy.
Soumoy L; Genbauffe A; Mouchart L; Sperone A; Trelcat A; Mukeba-Harchies L; Wells M; Blankert B; Najem A; Ghanem G; Saussez S; Journe F
Cancer Cell Int; 2024 Jan; 24(1):8. PubMed ID: 38178183
[TBL] [Abstract][Full Text] [Related]
2. Bufalin inhibits glioblastoma growth by promoting proteasomal degradation of the Na
Lan YL; Wang X; Lou JC; Xing JS; Yu ZL; Wang H; Zou S; Ma X; Zhang B
Biomed Pharmacother; 2018 Jul; 103():204-215. PubMed ID: 29653366
[TBL] [Abstract][Full Text] [Related]
3. Bufalin Inhibits Tumorigenesis and SREBP-1-Mediated Lipogenesis in Hepatocellular Carcinoma via Modulating the ATP1A1/CA2 Axis.
Huang CJ; Zhang CY; Zhao YK; Wang D; Zhuang L; Qian L; Xie L; Zhu Y; Meng ZQ
Am J Chin Med; 2023; 51(2):461-485. PubMed ID: 36655687
[TBL] [Abstract][Full Text] [Related]
4. The sodium pump α1 subunit regulates bufalin sensitivity of human glioblastoma cells through the p53 signaling pathway.
Lan YL; Zou YJ; Lou JC; Xing JS; Wang X; Zou S; Ma BB; Ding Y; Zhang B
Cell Biol Toxicol; 2019 Dec; 35(6):521-539. PubMed ID: 30739221
[TBL] [Abstract][Full Text] [Related]
5. ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells.
Burkard C; Verheije MH; Haagmans BL; van Kuppeveld FJ; Rottier PJ; Bosch BJ; de Haan CA
J Virol; 2015 Apr; 89(8):4434-48. PubMed ID: 25653449
[TBL] [Abstract][Full Text] [Related]
6. Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway.
Yang L; Zhou F; Zhuang Y; Liu Y; Xu L; Zhao H; Xiang Y; Dai X; Liu Z; Huang X; Wang L; Zhao C
Br J Cancer; 2021 Feb; 124(3):645-657. PubMed ID: 33122847
[TBL] [Abstract][Full Text] [Related]
7. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.
Liu X; Xiao XY; Shou QY; Yan JF; Chen L; Fu HY; Wang JC
J Ethnopharmacol; 2016 Dec; 193():538-545. PubMed ID: 27686271
[TBL] [Abstract][Full Text] [Related]
8. Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin.
Zhang Y; Dong Y; Melkus MW; Yin S; Tang SN; Jiang P; Pramanik K; Wu W; Kim S; Ye M; Hu H; Lu J; Jiang C
Mol Cancer Ther; 2018 Nov; 17(11):2341-2352. PubMed ID: 30166403
[TBL] [Abstract][Full Text] [Related]
9. Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells.
Gu W; Liu L; Fang FF; Huang F; Cheng BB; Li B
Oncol Rep; 2014 Jan; 31(1):216-22. PubMed ID: 24173654
[TBL] [Abstract][Full Text] [Related]
10. Bufalin inhibits peritoneal dissemination of gastric cancer through endothelial nitric oxide synthase-mitogen-activated protein kinases signaling pathway.
Zou D; Song J; Deng M; Ma Y; Yang C; Liu J; Wang S; Wen Z; Tang Y; Qu X; Zhang Y
FASEB J; 2021 May; 35(5):e21601. PubMed ID: 33913201
[TBL] [Abstract][Full Text] [Related]
11. Bufalin attenuates the stage and metastatic potential of hepatocellular carcinoma in nude mice.
Zhang ZJ; Yang YK; Wu WZ
J Transl Med; 2014 Feb; 12():57. PubMed ID: 24581171
[TBL] [Abstract][Full Text] [Related]
12. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.
Gu C; Wang Y; Zhang L; Qiao L; Sun S; Shao M; Tang X; Ding P; Tang C; Cao Y; Zhou Y; Guo M; Wei R; Li N; Xiao Y; Duan J; Yang Y
J Exp Clin Cancer Res; 2022 Jan; 41(1):11. PubMed ID: 34991674
[TBL] [Abstract][Full Text] [Related]
13. Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/β-catenin signal pathway.
Zhang H; Dong X; Ding X; Liu G; Yang F; Song Q; Sun H; Chen G; Li S; Li Y; Wang M; Guo T; Zhang Z; Li B; Yang L
J Transl Med; 2023 Dec; 21(1):900. PubMed ID: 38082327
[TBL] [Abstract][Full Text] [Related]
14. [Effect of bufalin on proliferation and apoptosis through ERK/RSK2 pathway in human esophageal carcinoma cell line xenografts in nude mice].
Yue M; Liu XJ; Ding Y; Wang XL; Yang HC; Liu YP
Zhonghua Zhong Liu Za Zhi; 2016 May; 38(5):325-32. PubMed ID: 27188603
[TBL] [Abstract][Full Text] [Related]
15. ATP1A1 Integrates AKT and ERK Signaling via Potential Interaction With Src to Promote Growth and Survival in Glioma Stem Cells.
Yu Y; Chen C; Huo G; Deng J; Zhao H; Xu R; Jiang L; Chen S; Wang S
Front Oncol; 2019; 9():320. PubMed ID: 31114755
[TBL] [Abstract][Full Text] [Related]
16. The expression of the alpha1 subunit of Na
Nakamura K; Shiozaki A; Kosuga T; Shimizu H; Kudou M; Ohashi T; Arita T; Konishi H; Komatsu S; Kubota T; Fujiwara H; Okamoto K; Kishimoto M; Konishi E; Otsuji E
Gastric Cancer; 2021 Nov; 24(6):1278-1292. PubMed ID: 34251542
[TBL] [Abstract][Full Text] [Related]
17. Bufalin inhibits epithelial-mesenchymal transition and increases radiosensitivity of non-small cell lung cancer via inhibition of the Src signaling.
Wang Z; Liu F; Huang C; Zhang J; Wu J
J Thorac Dis; 2023 Jan; 15(1):123-134. PubMed ID: 36794138
[TBL] [Abstract][Full Text] [Related]
18. Molecular and metabolic mechanisms of bufalin against lung adenocarcinoma: New and comprehensive evidences from network pharmacology, metabolomics and molecular biology experiment.
Shi S; Zhao S; Tian X; Liu F; Lu X; Zang H; Li F; Xiang L; Li L; Jiang S
Comput Biol Med; 2023 May; 157():106777. PubMed ID: 36924737
[TBL] [Abstract][Full Text] [Related]
19. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Wang H; Zhang C; Chi H; Meng Z
Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
[TBL] [Abstract][Full Text] [Related]
20. Targeting poly (ADP-ribose) polymerase partially contributes to bufalin-induced cell death in multiple myeloma cells.
Huang H; Cao Y; Wei W; Liu W; Lu SY; Chen YB; Wang Y; Yan H; Wu YL
PLoS One; 2013; 8(6):e66130. PubMed ID: 23762475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
